期刊
CURRENT OPINION IN PEDIATRICS
卷 34, 期 4, 页码 407-413出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOP.0000000000001150
关键词
adolescents; algorithm; children; comorbidities; obesity
类别
This review discusses new medical and surgical options for treating children and adolescents with obesity, and the impact of COVID-19 on this population, emphasizing the importance of screening tests for rare genetic causes of obesity. It also highlights the positive effects of new medications and surgical therapies in treating obesity, underscoring that obesity is a chronic disease that requires early intervention.
Purpose of review In this review, we discuss new medical and surgical options for the treatment of children and adolescents with obesity. We review the impact of COVID-19 on this vulnerable population. We also discuss the recent availability of screening tests for rare genetic causes of obesity. Recent findings COVID-19 increased the prevalence of obesity among children and adolescents. This population is at increased risk for severe disease. The field of pediatric obesity has benefited from the approval of two new antiobesity medications: liraglutide and setmelanotide. We discuss indications for their use. New guidelines for surgical options for the treatment of children and adolescents with obesity are reviewed. These options are increasingly used as part of the comprehensive care for these children. The epidemic of childhood obesity continues. COVID-19 and the associated isolation contributed to the problem. However, promising new medical and surgical therapies and screening tests for rare genetic causes of obesity are available. These new diagnostic and therapeutic options bring renewed enthusiasm to the treatment of children and adolescents with obesity and increased recognition that obesity is a chronic disease starting in childhood deserving intervention to prevent consequences.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据